Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis

Documenti analoghi

• Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma
  di: Pooneh Soltantabar, et al.
  Pubblicazione: (2025)
• A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients
  di: Donald Irby, et al.
  Pubblicazione: (2025)
• Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL‐1: Clinical Pharmacology Results
  di: Jue Gong, et al.
  Pubblicazione: (2025)
• A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
  di: Chi‐Chung Li, et al.
  Pubblicazione: (2024)
• Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins
  di: Yow‐Ming C. Wang, et al.
  Pubblicazione: (2024)